Regeneron Pharmaceuticals, Inc. Plans Quarterly Dividend of $0.88 (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) declared a quarterly dividend on Tuesday, February 4th,RTT News reports. Shareholders of record on Thursday, February 20th will be paid a dividend of 0.88 per share by the biopharmaceutical company on Thursday, March 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $724.23 on Wednesday. Regeneron Pharmaceuticals has a one year low of $642.00 and a one year high of $1,211.20. The company has a market capitalization of $79.59 billion, a price-to-earnings ratio of 17.96, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The company’s 50-day moving average is $718.04 and its 200 day moving average is $916.32. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $11.86 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals will post 37.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on REGN. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, Barclays dropped their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $982.43.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.